Outsourcing is the buzzword in the healthcare industry in the U.S., the rising cost of healthcare, less availability of man power, and quality worked provided by the vendors, are some of the factors driving the outsourcing of healthcare. There are three main segments of healthcare outsourcing covered in the report i.e.; payer, provider, and pharmaceutical. The payer (healthcare insurance companies), provider (hospitals) and the pharmaceutical companies are looking at outsourcing as a viable option to be competitive in the business. Healthcare reforms introduced by Obama government are also driving the healthcare outsourcing market.

The global healthcare BPO market is growing at a healthy CAGR of 21.4%. Pharmaceutical outsourcing accounts for the largest share of 64.3%, but will grow at a CAGR of 14.6% from 2011 to 2016 since the market is saturated. Healthcare provider outsourcing has the highest growth rate of 31.9% from 2011 to 2016 due to conversion from ICD-9 coding system to ICD-10 and ICD-10 coding system to be implemented by October  2013 in the U.S. Healthcare payer outsourcing market will also grow at about 30% in the forecast period.

U.S. is the largest source of outsourcing, followed by Europe. The most preferred destination is India in payer and provider outsourcing, whereas on shoring is the most preferred option for pharmaceutical outsourcing. Philippines is an upcoming destination making its mark in payer and provider outsourcing. India has advantages when compared to the other outsourcing destinations such as has availability of high number of healthcare professionals, affordable cost of living, large patient pool, and decreased time and cost of recruitment.

The overall healthcare BPO market is highly fragmented and there are many small players trying to take their share in the pie particularly in India and China, where many entrepreneurs have entered the market to meet the growing requirements. The major players in the payer and provider outsourcing market are Accenture (Ireland), Medusind (U.S.), GeBBS Healthcare (U.S.), Omega Healthcare (India), and Inventive (U.S.). The pharmaceutical outsourcing market is captured by players such as Quintiles (U.S.), Covance (U.S.), PPD (U.S.), Parexel (U.S.), Charles Rivers Laboratories (U.S.) and ICON (Ireland) in the CRO space; while in the CMO market the major competitors are Lonza (Switzerland), Catalent (U.S.), Boehringer Ingelheim (Germany), DSM Pharma (U.S.), and Jubilant Life Sciences (India).

Scope of the report

This healthcare BPO market research report evaluates the global Healthcare Business Process Outsourcing Market with respect to the services market. The report analyzes geography; forecasting revenues, and trends in each of the following submarkets:

• Payer
  • Claims processing
  • HR services
  • Member services/customer Care
  • Finance and accounts
• Provider
  • Medical billing
  • Medical coding
  • Medical transcription
  • Finance and accounts
• Pharmaceutical
  • Contract manufacturing organization
    • API manufacturing
    • Formulation & packaging
  • Clinical research organization
    • Drug discovery
    • Pre-clinical
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
    • CDM & biostatistics
    • Medical writing
    • Regulatory
    • Others
  •  Non-clinical services
    • SCM & logistics
    • Sales & marketing
    • Other functions

The geographies covered under the report are

• Source
  • U.S.
  • Europe
  • ROW 
• Destination
  • India
  • China
  • Philippines
  • On-shore U.S.
  • Eastern Europe
  • Middle East
  • LATAM (Latin American)

Each section provides market data, market drivers, trends and opportunities, key players, and competitive outlook. This report also provides market tables for covering the sub-segments and micro-markets. In addition, it makes ways for company profiles that cover all the sub-segments. As such, the report leaves no stone unturned in apprising about the past, present, and future of the global healthcare BPO market.

TABLE OF CONTENTS     
     
1 INTRODUCTION    
  1.1 KEY TAKE-AWAYS    
  1.2 REPORT DESCRIPTION    
  1.3 MARKETS COVERED    
  1.4 STAKEHOLDERS    
  1.5 RESEARCH METHODOLOGY    
      1.5.1 MARKET SIZE    
      1.5.2 MARKET SHARE    
      1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES    
      1.5.4 ASSUMPTIONS    
     
2 EXECUTIVE SUMMARY    
     
3 MARKET OVERVIEW    
  3.1 INTRODUCTION    
      3.1.1 DEFINITION    
      3.1.2 MARKET SEGMENTATION    
  3.2 MARKET DYNAMICS    
      3.2.1 DRIVERS    
            3.2.1.1 Introduction of Patient Protection & Affordable Care Act (PPACA) in U.S. adding 30 million people to the insurance regime    
            3.2.1.2 Helps focusing on core business areas    
            3.2.1.3 Need of the hour to reduce costs    
            3.2.1.4 Reduces overheads    
      3.2.2 RESTRAINTS    
            3.2.2.1 Unforeseen costs    
            3.2.2.2 Confidentiality and security of data is a major concern   
            3.2.2.3 Loss of managerial control    
      3.2.3 OPPORTUNITIES    
            3.2.3.1 Currently only 10% of the U.S. work is outsourced               
            3.2.3.2 Warehousing of data    
  3.3 TRENDS    
      3.3.1 INCREASING OUTSOURCING OF KNOWLEDGE PROCESSES    
      3.3.2 RISK IS BEING SHARED BETWEEN PAYER & PROVIDERS    
      3.3.3 PLATFORM-BASED BPO    
  3.4 BURNING ISSUES    
      3.4.1 ICD-10 CONVERSION    
      3.4.2 EHR AFFECTING MEDICAL TRANSCRIPTION    
      3.4.3 OBAMA HEALTHCARE REFORM    
  3.5 MARKET SHARE ANALYSIS    
      3.5.1 CRO    
      3.5.2 CMO    
  3.6 ADVANTAGE INDIA    
      3.6.1 WELL TRAINED MAN POWER    
      3.6.2 COST ADVANTAGE    
      3.6.3 LARGE PATIENT POOL    
      3.6.4 REGULATORY COMPLIANCE    
      3.6.5 FAST TURNAROUND TIME    
     
4 HEALTHCARE PAYER OUTSOURCING MARKET    
  4.1 INTRODUCTION    
  4.2 DRIVERS    
      4.2.1 END-TO-END SERVICES ARE PROVIDED    
      4.2.2 PPACA WILL ADD APPROXIMATELY 30 MILLION AMERICANS TO INSURANCE SYSTEM   
4.3 RESTRAINTS    
      4.3.1 REPUTATION OF A COMPANY IS AT A STAKE    
      4.3.2 A SINGLE MISTAKE CAN LEAD TO MILLIONS OF LOSS    
  4.4 CLAIMS PROCESSING    
  4.5 HR SERVICES    
  4.6 MEMBER SERVICES/CUSTOMER CARE    
  4.7 FINANCE & ACCOUNTS    
     
5 HEALTHCARE PROVIDER OUTSOURCING MARKET    
  5.1 INTRODUCTION    
  5.2 DRIVERS    
      5.2.1 DOMAIN KNOWLEDGE HELPS IN INCREASING REVENUE    
      5.2.2 INCREASING SAFETY OF THE PROCESSES    
  5.3 RESTRAINTS    
      5.3.1 DETERIORATING QUALITY OF SERVICE    
      5.3.2 PRIVACY & SECURITY CONCERNS    
  5.4 MEDICAL BILLING    
  5.5 MEDICAL CODING    
  5.6 MEDICAL TRANSCRIPTION    
  5.7 FINANCE & ACCOUNTS    
  5.8 KEY OPPORTUNITY ANALYSIS    
      5.8.1 TELERADIOLOGY    
      5.8.2 MEDICAL GRAPHICS    
     
6 GLOBAL PHARMACEUTICAL OUTSOURCING MARKET    
  6.1 INTRODUCTION    
  6.2 MARKET DYNAMICS    
      6.2.1 DRIVERS    
            6.2.1.1 Rising costs and decreasing productivity is compelling pharmaceutical companies to outsource    
            6.2.1.2 Thin product pipeline & many drugs going off patent will drive the outsourcing business    
            6.2.1.3 Desire to gain access to new technologies, one of the key drivers    
            6.2.1.4 Strategy to concentrate on core competencies & high margin products compels companies to outsource    
            6.2.1.5 Emergence of biologics to be one of the major drivers in the future    
            6.2.1.6 Increasing safety standards and closure of assets to drive the business to the outsourcing partners    
      6.2.2 RESTRAINTS    
            6.2.2.1 Quality control issues limit outsourcing    
            6.2.2.2 Regulatory barriers in different countries    
            6.2.2.3 Differences in the East/West disease profiles inhibits outsourcing to specific regions    
      6.2.3 OPPORTUNITIES    
            6.2.3.1 Outsourcing of supply chain & logistics    
            6.2.3.2 Outsourcing of sales & marketing functions    
            6.2.3.3 Outsourcing medical writing & regulatory functions, a major opportunity    
  6.3 MARKET TRENDS    
  6.4 GLOBAL CRO MARKET    
      6.4.1 OVERVIEW    
      6.4.2 GLOBAL DRUG DISCOVERY OUTSOURCING MARKET    
      6.4.3 GLOBAL PRE-CLINICAL SERVICES OUTSOURCING MARKET    
      6.4.4 GLOBAL CLINICAL DEVELOPMENT PHASE I OUTSOURCING MARKET    
      6.4.5 GLOBAL CLINICAL DEVELOPMENT PHASE II OUTSOURCING MARKET    
      6.4.6 GLOBAL CLINICAL DEVELOPMENT PHASE III OUTSOURCING MARKET    
      6.4.7 GLOBAL CLINICAL DEVELOPMENT PHASE IV OUTSOURCING MARKET    
      6.4.8 GLOBAL CLINICAL DATA MANAGEMENT (CDM) & BIOSTATISTICS OUTSOURCING MARKET    
      6.4.9 GLOBAL MEDICAL WRITING OUTSOURCING MARKET    
      6.4.10 GLOBAL REGULATORY SERVICES OUTSOURCING MARKET    
      6.4.11 GLOBAL CRO OTHER SERVICES (CENTRAL LAB & BASIC RESEARCH) OUTSOURCING MARKET    
  6.5 GLOBAL CMO MARKET    
      6.5.1 OVERVIEW    
      6.5.2 GLOBAL API MANUFACTURING OUTSOURCING MARKET    
      6.5.3 GLOBAL FORMULATION & PACKAGING OUTSOURCING MARKET    
  6.6 GLOBAL NON-CLINICAL SERVICES PHARMACEUTICAL OUTSOURCING MARKET    
      6.6.1 OVERVIEW    
      6.6.2 GLOBAL SUPPLY-CHAIN MANAGEMENT & LOGISTICS OUTSOURCING MARKET    
      6.6.3 GLOBAL SALES & MARKETING MANAGEMENT OUTSOURCING    
      6.6.4 GLOBAL CMO OTHER NON-CLINICAL FUNCTIONS OUTSOURCING    
     
7 GEOGRAPHICAL ANALYSIS    
  7.1 OVERVIEW    
  7.2 SOURCE    
      7.2.1 U.S.    
      7.2.2 EUROPE    
      7.2.3 REST OF THE WORLD    
  7.3 DESTINATION    
      7.3.1 INDIA    
            7.3.1.1 Payer & Provider    
            7.3.1.2 Pharmaceutical outsourcing    
                    7.3.1.2.1 Drivers & opportunities    
                              7.3.1.2.1.1 Combination of low cost and quality service drives Indian pharmaceutical outsourcing market    
                              7.3.1.2.1.2 Government support and improving infrastructure to drive the Indian pharmaceutical outsourcing    
                              7.3.1.2.1.3 Faster patient recruitment saves time and money    
                              7.3.1.2.1.4 Easy patent laws will boost outsourcing business    
                              7.3.1.2.1.5 Opportunities in outsourcing research biology & chemistry and pre-clinical studies to India    
                              7.3.1.2.1.6 Outsourcing of non-clinical services    
                              7.3.1.2.1.7 Medical tourism – a fast growing concept    
                    7.3.1.2.2 Restraints    
                              7.3.1.2.2.1 Healthcare reform to inhibit the Indian outsourcing business post 2013    
                              7.3.1.2.2.2 End-to-end services, not a practical option in India    
                    7.3.1.2.3 Market trends    
                    7.3.1.2.4 Regulations & Policies    
            7.3.1.3 Indian CRO market    
            7.3.1.4 Indian CMO market    
            7.3.1.5 Indian non-clinical outsourcing market    
      7.3.2 CHINA    
            7.3.2.1 Payer & Provider    
            7.3.2.2 Pharmaceutical outsourcing    
                    7.3.2.2.1 Drivers & opportunities    
                              7.3.2.2.1.1 Low cost and quality service, the major factor to drive the outsourcing business    
                              7.3.2.2.1.2 Talent pool and skilled labor to drive the Chinese pharmaceutical outsourcing market in long run    
                              7.3.2.2.1.3 Tax incentives attract foreign investors which in-turn drives the Chinese outsourcing business    
                              7.3.2.2.1.4 Large patient pool: Easier to find and recruit patients    
                              7.3.2.2.1.5 Cheap and rich animal resources saves cost of pre-clinical testing    
                              7.3.2.2.1.6 Pre-clinical development services are of high-quality    
                              7.3.2.2.1.7 Fast growing pharmaceutical market creates an opportunity for on-shore manufacturing in China    
                    7.3.2.2.2 Restraints    
                              7.3.2.2.2.1 Low service quality and capability to hamper Chinese outsourcing market    
                              7.3.2.2.2.2 IP protection and regulation - a barrier    
                    7.3.2.2.3 Regulations & Policies    
            7.3.2.3 Chinese CRO market    
            7.3.2.4 Chinese CMO market    
            7.3.2.5 Chinese non-clinical outsourcing market    
      7.3.3 U.S.    
            7.3.3.1 Payer & Provider    
            7.3.3.2 Pharmaceutical outsourcing    
                    7.3.3.2.1 Drivers & opportunities    
                              7.3.3.2.1.1 Finest healthcare system in the world    
                              7.3.3.2.1.2 Heterogeneous study population    
                              7.3.3.2.1.3 Most experienced physicians and investigators, a factor to keep the U.S. on the top    
                              7.3.3.2.1.4 Healthcare reform    
                    7.3.3.2.2 Restraints    
                              7.3.3.2.2.1 Competition from the Asian countries & high cost of research & production to restrict the growth    
                    7.3.3.2.3 Regulations & Policies    
            7.3.3.3 U.S. CRO market    
            7.3.3.4 U.S. CMO market    
            7.3.3.5 U.S. non-clinical outsourcing market    
      7.3.4 EUROPE    
            7.3.4.1 Payer and Provider    
            7.3.4.2 Europe Pharmaceutical Outsourcing    
                    7.3.4.2.1 Drivers    
                              7.3.4.2.1.1 Skilled physicians and experienced investigators to drive the European market    
                              7.3.4.2.1.2 European Union Clinical Trials Directive - an advantage    
                              7.3.4.2.1.3 Linguistic and cultural similarities allow cross-regional trials    
                              7.3.4.2.1.4 Excellent healthcare system in western European region - a plus point    
                              7.3.4.2.1.5 Large population with centralized healthcare system and high treatment-naïve patients in CEE region    
                              7.3.4.2.1.6 Lower costs in CEE countries - an obvious driver    
                    7.3.4.2.2 Restraints    
                              7.3.4.2.2.1 High clinical development cost    
                              7.3.4.2.2.2 Cultural dissimilarities and regional biases affect the outsourcing business in Europe    
                              7.3.4.2.2.3 Competition to CEE countries from low-cost Asian CMOs    
                    7.3.4.2.3 Regulations & Policies    
            7.3.4.3 European CRO market    
            7.3.4.4 European CMO market    
            7.3.4.5 European non-clinical outsourcing market    
      7.3.5 REST OF THE WORLD    
            7.3.5.1 Philippines    
                    7.3.5.1.1 Payer & Provider    
            7.3.5.2 LATAM    
                    7.3.5.2.1 Payer & Provider    
            7.3.5.3 Middle East    
                    7.3.5.3.1 Payer & Provider    
            7.3.5.4 Pharmaceutical outsourcing (including LATAM, Middle East, & Philippines)    
                    7.3.5.4.1 Drivers    
                              7.3.5.4.1.1 Proximity to the U.S. and improving healthcare infrastructure to drive LATAM outsourcing business    
                              7.3.5.4.1.2 Diverse and treatment naïve population of LATAM can drive CRO market    
                              7.3.5.4.1.3 Relationship with KOLs and high poverty rates in small countries    
                              7.3.5.4.1.4 The regulatory framework and ICH-GCP standard in Australia    
                    7.3.5.4.2 Restraints    
                              7.3.5.4.2.1 Rigid regulatory environment in LATAM    
                              7.3.5.4.2.2 Lack of investigator education in LATAM    
                              7.3.5.4.2.3 Limited language scope in LATAM    
                              7.3.5.4.2.4 Population size and geographical distance from the western countries - a barrier    
                              7.3.5.4.2.5 Competition from the Asian countries    
                    7.3.5.4.3 Regulations & policies    
            7.3.5.5 ROW CRO market    
            7.3.5.6 ROW CMO market    
            7.3.5.7 ROW non-clinical services outsourcing market    
     
8 COMPETITIVE LANDSCAPE    
  8.1 INTRODUCTION    
  8.2 MERGERS & ACQUISITIONS    
  8.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, JOINT VENTURES    
  8.4 NEW PRODUCTS LAUNCH    
  8.5 OTHER DEVELOPMENTS    
     
9 COMPANY PROFILES    
  9.1 ACCENTURE PLC    
      9.1.1 OVERVIEW    
      9.1.2 FINANCIALS    
      9.1.3 PRODUCTS & SERVICES    
      9.1.4 STRATEGY    
      9.1.5 DEVELOPMENTS    
  9.2 ACCRETIVE HEALTH INC    
      9.2.1 OVERVIEW    
      9.2.2 FINANCIALS    
      9.2.3 PRODUCTS & SERVICES    
      9.2.4 STRATEGY    
      9.2.5 DEVELOPMENTS    
  9.3 ANTHELIO HEALTHCARE SOLUTIONS INC    
      9.3.1 OVERVIEW    
      9.3.2 FINANCIALS    
      9.3.3 PRODUCTS & SERVICES    
      9.3.4 STRATEGY    
      9.3.5 DEVELOPMENTS    
  9.4 BOEHRINGER INGELHEIM GMBH    
      9.4.1 OVERVIEW    
      9.4.2 FINANCIALS    
      9.4.3 PRODUCTS & SERVICES    
      9.4.4 STRATEGY    
      9.4.5 DEVELOPMENTS    
  9.5 CATALENT PHARMA SOLUTIONS INC    
      9.5.1 OVERVIEW    
      9.5.2 FINANCIALS    
      9.5.3 PRODUCTS & SERVICES    
      9.5.4 STRATEGY    
      9.5.5 DEVELOPMENTS    
  9.6 CHARLES RIVER LABORATORIES INTERNATIONAL INC    
      9.6.1 OVERVIEW    
      9.6.2 FINANCIALS    
      9.6.3 PRODUCTS & SERVICES    
      9.6.4 STRATEGY    
      9.6.5 DEVELOPMENTS    
  9.7 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION    
      9.7.1 OVERVIEW    
      9.7.2 FINANCIALS    
      9.7.3 PRODUCTS & SERVICES    
      9.7.4 STRATEGY    
      9.7.5 DEVELOPMENTS    
  9.8 COVANCE INC    
      9.8.1 OVERVIEW    
      9.8.2 FINANCIALS    
      9.8.3 PRODUCTS & SERVICES    
      9.8.4 STRATEGY    
      9.8.5 DEVELOPMENTS    
  9.9 GEBBS HEALTHCARE SOLUTIONS INC    
      9.9.1 OVERVIEW    
      9.9.2 FINANCIALS    
      9.9.3 PRODUCTS & SERVICES    
      9.9.4 STRATEGY    
      9.9.5 DEVELOPMENTS     
  9.10 GENPACT LIMITED    
      9.10.1 OVERVIEW    
      9.10.2 FINANCIALS    
      9.10.3 PRODUCTS & SERVICES    
      9.10.4 STRATEGY    
      9.10.5 DEVELOPMENTS    
  9.11 IBM GLOBAL PROCESS SERVICES    
      9.11.1 OVERVIEW    
      9.11.2 FINANCIALS    
      9.11.3 PRODUCTS & SERVICES    
      9.11.4 STRATEGY    
      9.11.5 DEVELOPMENT    
  9.12 ICON PLC    
      9.12.1 OVERVIEW    
      9.12.2 FINANCIALS    
      9.12.3 PRODUCTS & SERVICES    
      9.12.4 STRATEGY    
      9.12.5 DEVELOPMENTS    
  9.13 IGATE PATNI    
      9.13.1 OVERVIEW    
      9.13.2 FINANCIALS    
      9.13.3 PRODUCTS & SERVICES    
      9.13.4 STRATEGY    
      9.13.5 DEVELOPMENTS    
  9.14 INFOSYS BPO    
      9.14.1 OVERVIEW    
      9.14.2 FINANCIALS    
      9.14.3 PRODUCTS & SERVICES    
      9.14.4 STRATEGY    
      9.14.5 DEVELOPMENT    
  9.15 INVENTIV HEALTH INC    
      9.15.1 OVERVIEW    
      9.15.2 FINANCIALS    
      9.15.3 PRODUCTS & SERVICES    
      9.15.4 STRATEGY    
      9.15.5 DEVELOPMENTS    
  9.16 LONZA GROUP LTD    
      9.16.1 OVERVIEW    
      9.16.2 FINANCIALS    
      9.16.3 PRODUCTS & SERVICES    
      9.16.4 STRATEGY    
      9.16.5 DEVELOPMENTS    
  9.17 MAHINDRA SATYAM    
      9.17.1 OVERVIEW    
      9.17.2 FINANCIALS    
      9.17.3 PRODUCTS & SERVICES    
      9.17.4 STRATEGY    
      9.17.5 DEVELOPMENTS    
  9.18 MEDUSIND SOLUTIONS INC    
      9.18.1 OVERVIEW    
      9.18.2 FINANCIALS    
      9.18.3 PRODUCTS & SERVICES    
      9.18.4 STRATEGY    
      9.18.5 DEVELOPMENTS    
      9.19 MPHASIS LIMITED    
      9.19.1 OVERVIEW    
      9.19.2 FINANCIALS    
      9.19.3 PRODUCTS & SERVICES    
      9.19.4 STRATEGY    
      9.19.5 DEVELOPMENTS    
  9.20 OMEGA HEALTHCARE MANAGEMENT SERVICES PVT LTD    
      9.20.1 OVERVIEW    
      9.20.2 FINANCIALS    
      9.20.3 PRODUCTS & SERVICES    
      9.20.4 STRATEGY    
      9.20.5 DEVELOPMENT    
  9.21 PAREXEL INTERNATIONAL CORPORATION    
      9.21.1 OVERVIEW    
      9.21.2 FINANCIALS    
      9.21.3 PRODUCTS & SERVICES    
      9.21.4 STRATEGY    
      9.21.5 DEVELOPMENTS    
  9.22 PATHEON INC    
      9.22.1 OVERVIEW    
      9.22.2 FINANCIALS    
      9.22.3 PRODUCTS & SERVICES    
      9.22.4 STRATEGY    
      9.22.5 DEVELOPMENTS    
  9.23 PHARMACEUTICAL PRODUCT DEVELOPMENT INC    
      9.23.1 OVERVIEW    
      9.23.2 FINANCIALS    
      9.23.3 PRODUCTS & SERVICES    
      9.23.4 STRATEGY    
      9.23.5 DEVELOPMENTS    
  9.24 PIRAMAL LIFE SCIENCES LIMITED    
      9.24.1 OVERVIEW    
      9.24.2 FINANCIALS    
      9.24.3 PRODUCTS & SERVICES    
      9.24.4 STRATEGY    
      9.24.5 DEVELOPMENTS    
  9.25 QUINTILES TRANSNATIONAL CORPORATION    
      9.25.1 OVERVIEW    
      9.25.2 FINANCIALS    
      9.25.3 PRODUCTS & SERVICES    
      9.25.4 STRATEGY    
      9.25.5 DEVELOPMENTS    
  9.26 TATA CONSULTANCY SERVICES LTD    
      9.26.1 OVERVIEW    
      9.26.2 FINANCIALS    
      9.26.3 PRODUCTS & SERVICES    
      9.26.4 STRATEGY    
      9.26.5 DEVELOPMENTS    
  9.27 TELERADIOLOGY SOLUTIONS PVT LTD.    
      9.27.1 OVERVIEW    
      9.27.2 FINANCIALS    
      9.27.3 PRODUCTS & SERVICES    
      9.27.4 STRATEGY    
      9.27.5 DEVELOPMENTS    
  9.28 WNS HOLDINGS LTD    
      9.28.1 OVERVIEW    
      9.28.2 FINANCIALS    
      9.28.3 PRODUCTS & SERVICES    
      9.28.4 STRATEGY    
      9.28.5 DEVELOPMENTS     
      
     
LIST OF TABLES     
     
TABLE 1 GLOBAL HEALTHCARE OUTSOURCING MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION)     
TABLE 2 GLOBAL HEALTHCARE PAYER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 3 HEALTHCARE PAYER OUTSOURCING MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 4 HEALTHCARE PAYER OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($MILLION)     
TABLE 5 HEALTHCARE PAYER CLAIMS PROCESSING OUTSOURCING MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 6 HEALTHCARE PAYER CLAIMS PROCESSING OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 7 HEALTHCARE PAYER HR SERVICES OUTSOURCING MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 8 HEALTHCARE PAYER HR SERVICES OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 9 HEALTHCARE PAYER MEMBER SERVICES/CUSTOMER CARE OUTSOURCING MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($MILLION)     
TABLE 10 HEALTHCARE PAYER MEMBER SERVICES/CUSTOMER CARE OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 11 HEALTHCARE PAYER FINANCE & ACCOUNTS OUTSOURCING MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 12 HEALTHCARE PAYER FINANCE & ACCOUNTS OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 13 GLOBAL HEALTHCARE PROVIDER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 14 HEALTHCARE PROVIDER OUTSOURCING MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 15 HEALTHCARE PROVIDER OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($MILLION)     
TABLE 16 HEALTHCARE PROVIDER MEDICAL BILLING OUTSOURCING MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 17 HEALTHCARE PROVIDER MEDICAL BILLING OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 18 HEALTHCARE PROVIDER MEDICAL CODING OUTSOURCING MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 19 HEALTHCARE PROVIDER MEDICAL CODING OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 20 HEALTHCARE PROVIDER MEDICAL TRANSCRIPTION OUTSOURCING MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 21 HEALTHCARE PROVIDER MEDICAL TRANSCRIPTION OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 22 HEALTHCARE PROVIDER FINANCE & ACCOUNTS OUTSOURCING MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 23 HEALTHCARE PROVIDER FINANCE & ACCOUNTS OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($MILLION)    
TABLE 24 GLOBAL PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($BILLION)     
TABLE 25 PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 26 PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 27 GLOBAL CRO MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 28 CRO MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 29 CRO MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 30 DRUG DISCOVERY OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 31 PRE-CLINICAL SERVICES OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)     
TABLE 32 CLINICAL DEVELOPMENT PHASE I OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 33 CLINICAL DEVELOPMENT PHASE II OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 34 CLINICAL DEVELOPMENT PHASE III OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 35 CLINICAL DEVELOPMENT PHASE IV OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 36 CLINICAL DATA MANAGEMENT & BIOSTATISTICS OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 37 MEDICAL WRITING OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 38 REGULATORY SERVICES OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)     
TABLE 39 CRO OTHER SERVICES OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)     
TABLE 40 GLOBAL CMO MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 41 CMO MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 42 CMO MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 43 API MANUFACTURING OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)     
TABLE 44 FORMULATION & PACKAGING OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)     
TABLE 45 GLOBAL NON-CLINICAL SERVICES PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 46 NON-CLINICAL SERVICES PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 47 NON-CLINICAL SERVICES PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 48 SUPPLY-CHAIN MANAGEMENT & LOGISTICS OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 49 SALES & MARKETING MANAGEMENT OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 50 CMO OTHER NON-CLINICAL FUNCTIONS OUTSOURCING MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 51 HEALTHCARE BPO MARKET REVENUE, BY SOURCE GEOGRAPHY, 2009 – 2016 ($BILLION)     
TABLE 52 SOURCE U.S. HEALTHCARE BPO MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($BILLION)    
TABLE 53 SOURCE U.S. PAYER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)    
TABLE 54 SOURCE U.S. PROVIDER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 55 SOURCE U.S. PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)     
TABLE 56 SOURCE EUROPE HEALTHCARE BPO MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($BILLION)    
TABLE 57 SOURCE EUROPE PAYER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 58 SOURCE EUROPE PROVIDER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 59 SOURCE EUROPE PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 60 SOURCE ROW HEALTHCARE BPO MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($BILLION)    
TABLE 61 SOURCE ROW PAYER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)    
TABLE 62 SOURCE ROW PROVIDER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 63 SOURCE ROW PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)     
TABLE 64 HEALTHCARE BPO MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2009 – 2016 ($BILLION)    
TABLE 65 DESTINATION INDIA HEALTHCARE OUTSOURCING MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION)    
TABLE 66 DESTINATION INDIA PAYER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 67 DESTINATION INDIA PROVIDER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 68 DESTINATION INDIA PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 69 DESTINATION INDIA CRO MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 70 DESTINATION INDIA CMO MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)     
TABLE 71 DESTINATION INDIA NON-CLINICAL OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 72 DESTINATION CHINA HEALTHCARE OUTSOURCING MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION)    
TABLE 73 DESTINATION CHINA PAYER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 74 DESTINATION CHINA PROVIDER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 75 DESTINATION CHINA PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 76 DESTINATION CHINA CRO MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 77 DESTINATION CHINA CMO MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)     
TABLE 78 DESTINATION CHINA NON-CLINICAL OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 79 DESTINATION U.S. HEALTHCARE OUTSOURCING MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION)     
TABLE 80 DESTINATION U.S. PAYER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 81 DESTINATION U.S PROVIDER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 82 DESTINATION U.S. PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 83 DESTINATION U.S. CRO MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 84 DESTINATION U.S. CMO MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 85 DESTINATION U.S. NON-CLINICAL OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 86 DESTINATION EUROPE HEALTHCARE OUTSOURCING MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION)    
TABLE 87 DESTINATION EUROPE PAYER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 88 DESTINATION EUROPE PROVIDER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)    
TABLE 89 DESTINATION EUROPE PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 90 DESTINATION EUROPE CRO MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)     
TABLE 91 DESTINATION EUROPE CMO MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)     
TABLE 92 DESTINATION EUROPE NON-CLINICAL OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 93 DESTINATION PHILIPPINES PAYER & PROVIDER OUTSOURCING MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION)    
TABLE 94 DESTINATION PHILIPPINES PAYER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)    
TABLE 95 DESTINATION PHILIPPINES PROVIDER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)    
TABLE 96 DESTINATION LATAM PAYER & PROVIDER OUTSOURCING MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION)    
TABLE 97 DESTINATION LATAM PAYER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 98 DESTINATION LATAM PROVIDER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)     
TABLE 99 DESTINATION MIDDLE EAST PAYER & PROVIDER OUTSOURCING MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION)    
TABLE 100 DESTINATION MIDDLE EAST PAYER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)    
TABLE 101 DESTINATION MIDDLE EAST PROVIDER OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($MILLION)    
TABLE 102 DESTINATION ROW PHARMACEUTICAL OUTSOURCING MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($BILLION)    
TABLE 103 DESTINATION ROW CRO MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)     
TABLE 104 DESTINATION ROW CMO MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)     
TABLE 105 DESTINATION ROW NON-CLINICAL SERVICES OUTSOURCING MARKET REVENUE, BY SERVICES, 2009 – 2016 ($BILLION)    
TABLE 106 MERGERS & ACQUISITIONS, JANUARY 2009 – DECEMBER 2011    
TABLE 107 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, JOINT VENTURES, JANUARY 2009 – DECEMBER 2011    
TABLE 108 NEW PRODUCTS LAUNCH, JANUARY 2009 – DECEMBER 2011    
TABLE 109 OTHER DEVELOPMENTS, JANUARY 2009 – NOVEMBER 2011    
TABLE 110 ACCENTURE PLC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)    
TABLE 111 ACCENTURE PLC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)    
TABLE 112 ACCENTURE PLC: MARKET REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)    
TABLE 113 ACCRETIVE HEALTH INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)     
TABLE 114 ACCRETIVE HEALTH INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)    
TABLE 115 BOEHRINGER INGELHEIM GMBH: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)    
TABLE 116 BOEHRINGER INGELHEIM GMBH: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)    
TABLE 117 BOEHRINGER INGELHEIM GMBH: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)    
TABLE 118 CATALENT PHARMA SOLUTIONS INC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)    
TABLE 119 CATALENT PHARMA SOLUTIONS INC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)    
TABLE 120 CATALENT PHARMA SOLUTIONS INC: MARKET REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)     
TABLE 121 CHARLES RIVER LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)    
TABLE 122 CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)    
TABLE 123 CHARLES RIVER LABORATORIES: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)    
TABLE 124 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: TOTAL REVENUE, 2008 – 2010 ($MILLION)    
TABLE 125 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)    
TABLE 126 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)    
TABLE 127 COVANCE INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)    
TABLE 128 COVANCE INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)    
TABLE 129 COVANCE INC: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)    
TABLE 130 GENPACT LIMITED: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)    
TABLE 131 GENPACT LIMITED: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)    
TABLE 132 GENPACT LIMITED: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)    
TABLE 133 IBM GLOBAL PROCESS SERVICES: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)    
TABLE 134 IBM GLOBAL PROCESS SERVICES: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)    
TABLE 135 IBM GLOBAL PROCESS SERVICES: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)    
TABLE 136 ICON PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)    
TABLE 137 ICON PLC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)    
TABLE 138 ICON PLC: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)    
TABLE 139 IGATE CORPORATION: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)     
TABLE 140 IGATE CORPORATION: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)    
TABLE 141 INFOSYS LIMITED: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)    
TABLE 142 INFOSYS LIMITED: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)    
TABLE 143 INFOSYS LIMITED: MARKET REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)    
TABLE 144 LONZA GROUP AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)    
TABLE 145 LONZA GROUP AG: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)    
TABLE 146 LONZA GROUP AG: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)    
TABLE 147 MAHINDRA SATYAM: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)     
TABLE 148 MAHINDRA SATYAM: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)    
TABLE 149 MAHINDRA SATYAM: MARKET REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)    
TABLE 150 MPHASIS LIMITED: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)    
TABLE 151 MPHASIS LIMITED: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)    
TABLE 152 MPHASIS LIMITED: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)    
TABLE 153 PAREXEL INTERNATIONAL CORPORATION: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)    
TABLE 154 PAREXEL INTERNATIONAL CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)     
TABLE 155 PAREXEL INTERNATIONAL CORPORATION: MARKET REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)     
TABLE 156 PATHEON INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)    
TABLE 157 PATHEON INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)    
TABLE 158 PPD INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)    
TABLE 159 PPD INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)    
TABLE 160 PPD INC: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)    
TABLE 161 PIRAMAL LIFE SCIENCES LTD: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)    
TABLE 162 TATA CONSULTANCY SERVICES LTD: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)    
TABLE 163 TATA CONSULTANCY SERVICES LTD: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)    
TABLE 164 TATA CONSULTANCY SERVICES LTD: MARKET REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)     
TABLE 165 WNS HOLDINGS LTD: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)     
TABLE 166 WNS HOLDINGS LTD: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)    
TABLE 167 WNS HOLDINGS LTD: MARKET REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)    
     
      
LIST OF FIGURES     
     
FIGURE 1 GLOBAL HEALTHCARE BPO MARKET REVENUE, BY SEGMENTS,
2009 – 2016 ($BILLION)     
FIGURE 2 MARKET SEGMENTATION OF HEALTHCARE BPO MARKET    
FIGURE 3 HEALTHCARE BPO MARKET DYNAMICS    
FIGURE 4 U.S. HEALTHCARE REFORMS AFFECTING THE HEALTHCARE BPO MARKET    
FIGURE 5 HEALTHCARE CONTRACT RESEARCH ORGANISATION MARKET SHARE ANALYSIS, 2010    
FIGURE 6 HEALTHCARE CONTRACT MANUFCATURING ORGANISATION MARKET SHARE ANALYSIS, 2010    
FIGURE 7 ADVANTAGES OF INDIA IN HEALTHCARE OUTSOURCING    
FIGURE 8 HEALTHCARE BPO PHARMACEUTICAL MARKET DYNAMICS    
FIGURE 9 HEALTHCARE BPO MARKET SHARE, BY SOURCE GEOGRAPHY, 2011    
FIGURE 10 HEALTHCARE BPO MARKET REVENUE, BY DESTINATION GEOGRAPHY, 2011    
FIGURE 11 KEY GROWTH STRATEGIES

Global Healthcare BPO Market is expected to reach $329 billion by 2016

Outsourcing is the strategic use of outside resources to perform activities traditionally done by internal staff and resources. Due to the globalization and opening up of economies which can provide work at a lower cost, outsourcing has proven to be asset to many companies giving them a strategic advantage.

The global healthcare BPO market is growing at a healthy CAGR of 21.4%. Pharmaceutical outsourcing accounts for the largest share of 64.3%, but will grow at a CAGR of 14.6% from 2011 to 2016 since the market is saturated. Healthcare provider outsourcing has the highest growth rate of 31.9%, healthcare payer outsourcing market will also grow at about 30% in the forecast period.

U.S. has the highest amount of expenditure on healthcare, accounting for 16% of its Gross Domestic Product (GDP). Hence the U.S government under the leadership of President Barack Obama has taken initiatives and is introducing reforms which will reduce the overall costs of healthcare and increase efficiency. The healthcare reforms affect the entire healthcare market, forcing the players to take timely measures to be in order with the changed rules and regulations.

U.S. HEALTHCARE REFORMS AFFECTING THE HEALTHCARE BPO MARKET

Source: Expert interviews, Annual report, MarketsandMarkets Analysis

This has affected the outsourcing market in a positive way, the healthcare payer has to follow the medical loss ratio decreasing the administrative expenses, it also has to face increased competition as the retail market is open and there are also 30 million new enrollees added to the insurance regime. The healthcare providers are to implement IT in there processes, ICD-10 which will increase the number of codes from 18,000 to 64,000 increasing the demand for trained coders and also decrease reimbursement forcing the providers to reduce cost. The pharmaceutical healthcare industry is affected in an indirect manner, with mounting pressure from both payer as well as providers to reduce costs, also the U.S. government signed a deal with pharmaceutical industry to provide drugs at reduced prices, decreasing their margins. As the reforms are implemented in phases it is an ongoing process.